SCHEMBL20522382

SCHEMBL20522382

COc1ccc(-c2ccccc2Nc2ccc(-c3nnc(N)s3)cc2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MGAM O43451 3/20 0.45
GAA P10253 3/20 0.45
SI P14410 3/20 0.45
MGAM2 Q2M2H8 3/20 0.45
QPCT Q16769 4/20 0.45
QPCTL Q9NXS2 3/20 0.45
GPX4 P36969 1/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
ADORA1 P30542 1/20 0.41
KIT P10721 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20522396 0.86 MEN1 (0.47) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL29550815 0.86 MEN1 (0.47) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL20522413 0.85 KDM4E (0.64) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL20522354 0.82 KDM4E (0.57) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL11334896 0.79 ALDH1A1 (0.63) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL20522390 0.79 KDM4E (0.49) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL22712380 0.78 KDM4E (0.53) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL20522325 0.78 MGAM (0.50) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL20522401 0.78 KDM4E (0.47) ALDH1A1KDM4EMAPTTP53HSD17B10
SCHEMBL22712382 0.77 HDAC1 (0.57) ALDH1A1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 US claimed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US claimed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US claimed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP claimed
CN-110719910-A Novel inhibitors 前体生物药物股份公司 2020-01-21 CN claimed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO claimed
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 CN disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
CN-110719910-A Novel inhibitors 前体生物药物股份公司 2020-01-21 CN disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 ALDH1A1 1183/4885KDM4E 1773/4885MAPT 3890/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT ALDH1A1 1681/4885KDM4E 1119/4885MAPT 2845/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS ALDH1A1 1490/4885KDM4E 1078/4885MAPT 2831/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 ALDH1A1 1415/4885KDM4E 1254/4885MAPT 1850/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT ALDH1A1 1184/4885KDM4E 1160/4885MAPT 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.